/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our approved product CARDAMYST TM (etripamil) nasal spray is available in the United States and is the first and only FDA approved self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs.
$0.92
$0.00 (-0.46%)
EOD Sep 18, 2026
ROIC dropped from -48.74% to -58.41%, capital efficiency is deteriorating. Negative free cash flow of -$49M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$84M
▼ -51.9% YoY
Op. Margin
—
ROIC
-70.48%
▼ -9.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$62M
▼ -70.8% YoY
Op. Cash Flow (TTM)
-$61M
▼ -70.0% YoY
Net Debt
-$111M
Net Cash Position
Cash & Equiv.
$171M
Continue Research
SourceComputed from the 10-Q filed 12 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.